News Sentiment

AVBP sentiment intelligence

ArriVent BioPharma, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 67 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 33.19 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 7

high-authority source matches

Trend context Trend active

-1.5% over one week, +4.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -1.5% Price digesting
Trend fit Trend active 4.6% over four weeks
Fair value 44.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 44
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 12
Stock Titan 5
Moomoo 4
TradingKey 4
simplywall.st 3
Seeking Alpha 3
Stock Traders Daily 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 25
Analyst action 5
Balance sheet 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 67
TradingKey Direct company coverage

Arrivent Biopharma Inc (AVBP) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Arrivent Biopharma Inc (AVBP), detailing analyst ratings, target prices, and future EPS and revenue growth estimates. Based on 13 analysts, the company currently holds a "Buy" rating with a target price of 43.917 USD, representing a

Tone
Neutral 50/100
Event
Earnings
Published
19 Jun 2026 02:39
Source
TradingKey
TradingKey Direct company coverage

Arrivent Biopharma Inc (AVBP) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Arrivent Biopharma Inc (AVBP) through TradingKey. It covers key financial metrics like cash and cash equivalents, total assets, liabilities, free cash flow, and operational efficiency. However, the analysis notes that relevant

Tone
Neutral 50/100
Event
Balance sheet
Published
19 Jun 2026 01:42
Source
TradingKey
TradingKey Direct company coverage

Arrivent Biopharma Inc (AVBP) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Arrivent Biopharma Inc (AVBP), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. However, it notes that relevant data for these valuation metrics have not yet been disclosed by the company. The article presents the company

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 01:39
Source
TradingKey
TradingKey Direct company coverage

Arrivent Biopharma Inc (AVBP) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Arrivent Biopharma Inc (AVBP), detailing its volatility, financial risk, and investment risk metrics. It includes data such as Beta vs S&P 500 index, Maximum Drawdown, 240-Day Volatility, and various return and liquidity indicators. The

Tone
Neutral 50/100
Event
Balance sheet
Published
19 Jun 2026 00:42
Source
TradingKey